Cullinan Therapeutics Q4 net loss widens

Cullinan Therapeutics

10/03/2026 11:07

Overview

Biopharmaceutical firm's Q4 operating income and pretax profit beat analyst expectations

Net loss for Q4 was $50.7 mln, up from last year

Company has $439 mln cash, providing runway into 2029

Outlook

Cullinan plans to share initial CLN-978 data in Q2 2026 for SLE and RA

Company expects repeat dosing data for CLN-978 in RA by Q3 2026

Cullinan anticipates CLN-049 Phase 1 update for AML in H2 2026

Result Drivers

CLN-978 PROGRESS - Strong enrollment momentum for CLN-978 positions Cullinan to deliver data for a potential best-in-class CD19 T cell engager in autoimmune diseases by Q2 2026

ZIPALERTINIB MILESTONE - Completion of rolling NDA submission for zipalertinib marks progress in collaboration with Taiho, with top-line results expected by year-end 2026

CASH RUNWAY - Cullinan reported $439 mln in cash and investments, providing operational runway into 2029

Company press release: ID:nGNX8KxCrM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$50.71 mln
Q4 Operating Income
Beat
-$55.26 mln
-$56.48 mln (11 Analysts)
Q4 Pretax Profit
Beat
-$50.71 mln
-$51.45 mln (11 Analysts)
Q4 Operating Expenses
$55.26 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $31.50, about 105.7% above its March 9 closing price of $15.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)